Skip to main content
Home > Week in Review > Other News

Chronological Index of BioCentury, Week in Review: Other News

BioCentury, Week in Review Current Issue
  • Accelr8 Technology, Denver Health & Hospital Authority diagnostic, infectious news

    Accelr8 Technology Corp. (NYSE-A:AXK), Denver, Colo. Denver Health & Hospital Authority, Denver, Colo. Business: Diagnostic, Infectious Accelr8 and Denver Health received notice that the U.S. Department of Defense's …

    Published on 5/21/2012
  • AstraZeneca, Boehringer Ingelheim, GlaxoSmithKline, J&J, Merck KGaA, Pfizer, University of Dundee cancer, autoimmune news

    AstraZeneca plc (LSE:AZN; NYSE:AZN), London, U.K. Boehringer Ingelheim GmbH, Ingelheim, Germany GlaxoSmithKline plc (LSE:GSK; NYSE:GSK), London, U.K. Johnson & Johnson (NYSE:JNJ), New Brunswick, N.J. Merck KGaA (Xetra:…

    Published on 5/21/2012
  • Dendreon cancer news

    Dendreon Corp. (NASDAQ:DNDN), Seattle, Wash. Business: Cancer Dendreon disclosed in a 10Q filing that the SEC is investigating the company. Dendreon said it does not know the specific focus of the investigation, but …

    Published on 5/21/2012
  • Fibrocell dermatology, neurology news

    Fibrocell Science Inc. (OTCBB:FCSC), Exton, Pa. Business: Dermatology, Neurology Fibrocell announced the formation of the Clinical Investigations for Dermal Mesenchymally-Obtained Derivatives (CIDMOD) Initiative to …

    Published on 5/21/2012
  • Medtronic musculoskeletal news

    Medtronic Inc. (NYSE:MDT), Minneapolis, Minn. Business: Musculoskeletal Medtronic said it received notice from the U.S. Department of Justice and the Office of the U.S. Attorney for the District of Massachusetts that …

    Published on 5/21/2012
  • Merck KGaA pharmaceuticals news

    Merck KGaA (Xetra:MRK), Darmstadt, Germany Business: Pharmaceuticals Merck hopes to achieve 300 million ($386.6 million) in net cost savings by 2014 through the previously announced restructuring of its Merck Serono …

    Published on 5/21/2012
  • Abbott neurology news

    Abbott Laboratories (NYSE:ABT), Abbott Park, Ill. Business: Neurology Abbott will pay $1.5 billion to federal and state authorities to resolve criminal and civil liability regarding past marketing activities for …

    Published on 5/14/2012
  • Actelion pharmaceuticals news

    Actelion Ltd. (SIX:ATLN), Allschwil, Switzerland Business: Pharmaceuticals Actelion said it plans to reduce R&D and overhead spending by refocusing R&D activities on specialty areas and out-licensing its primary care …

    Published on 5/14/2012
  • AMAG Pharmaceuticals hematology news

    AMAG Pharmaceuticals Inc. (NASDAQ:AMAG), Lexington, Mass. Business: Hematology Chairman Michael Narachi said it was time to shift AMAG's focus away from a potential sale of the company in order to grow sales of anemia …

    Published on 5/14/2012
  • Angel Biotech supply/service news

    Angel Biotechnology Holdings plc (LSE:ABH), Edinburgh, U.K. Business: Supply/Service Angel Biotechnology launched its new subsidiary Angel Biomedical Ltd., which acquired assets from an undisclosed biomaterial and …

    Published on 5/14/2012
  • Ark Therapeutics, University College London endocrine/metabolic news

    Ark Therapeutics Group plc (LSE:AKT), London, U.K. University College London, London, U.K. Business: Endocrine/Metabolic Ark said that a consortium led by the college received a six-year grant of up to 6 million ($7.9 …

    Published on 5/14/2012
  • Bio-Matrix Scientific gene/cell therapy news

    Bio-Matrix Scientific Group Inc. (OTCQB:BMSN; Pink:PMSN), La Mesa, Calif. Business: Gene/Cell therapy Bio-Matrix said it established subsidiary Regen BioPharma Inc. to develop stem cell therapies. Regen also secured $20…

    Published on 5/14/2012
  • Biolex infectious news

    Biolex Therapeutics Inc., Pittsboro, N.C. Business: Infectious Biolex said it is seeking to sell worldwide rights to its remaining asset, hepatitis candidate Locteron. The controlled-release formulation of recombinant …

    Published on 5/14/2012
  • Catalent Pharma, Profectus infectious, biomanufacturing news

    Catalent Pharma Solutions Inc., Somerset, N.J. Profectus BioSciences Inc., Baltimore, Md. Business: Infectious, Biomanufacturing Profectus said it received a $5.6 million grant from NIH's National Institute of Allergy …

    Published on 5/14/2012
  • China Nuokang hematology, cardiovascular news

    China Nuokang Bio-Pharmaceutical Inc. (NASDAQ:NKBP), Shenyang, China Business: Hematology, Cardiovascular China Nuokang's board received a preliminary, non-binding proposal from the company's CEO and Chairman Baizhong …

    Published on 5/14/2012
  • Helicos, Pacific Biosciences genomics news

    Helicos BioSciences Corp. (Pink:HLCS), Cambridge, Mass. Pacific Biosciences of California Inc. (NASDAQ:PACB), Menlo Park, Calif. Business: Genomics Pacific Biosciences said it and Helicos settled a 2010 suit in the U.S.…

    Published on 5/14/2012
  • Innovative Medicines Initiative (IMI), Juvenile Diabetes Research Foundation International (JDRF) endocrine/metabolic news

    Innovative Medicines Initiative (IMI), Brussels, Belgium Juvenile Diabetes Research Foundation International (JDRF), New York, N.Y. Business: Endocrine/Metabolic The EU's public-private Innovative Medicines Initiative …

    Published on 5/14/2012
  • Isogenica high throughput screening news

    Isogenica Ltd., Little Chesterford, U.K. Business: High throughput screening Isogenica said it received a three-year, 700,000 ($911,190) grant under the European Commission's Framework Programme 7 (FP7). The company …

    Published on 5/14/2012
  • Kineta, University of Washington, University of Texas Medical Branch infectious news

    Kineta Inc., Seattle, Wash. University of Washington, Seattle, Wash. University of Texas Medical Branch, Galveston, Texas Business: Infectious The NIH's National Institute of Allergy and Infectious Diseases (NIAID) …

    Published on 5/14/2012
  • Porphylix hematology news

    Prophylix Pharma A/S, Tromso, Norway Business: Hematology Prophylix said PROFNAIT, a consortium led by the company, will receive a grant of up to 6 million ($7.8 million) from the European Commission's Framework …

    Published on 5/14/2012
  • Qiagen, Bill & Melinda Gates Foundation, Grand Challenges Canada diagnostic news

    Qiagen N.V. (Xetra:QIA; NASDAQ:QGEN), Venlo, the Netherlands Bill & Melinda Gates Foundation, Seattle, Wash. Grand Challenges Canada, Toronto, Ontario Business: Diagnostic Qiagen joined the Point-of-Care Diagnostics …

    Published on 5/14/2012
  • Repligen diagnostic news

    Repligen Corp. (NASDAQ:RGEN), Waltham, Mass. Business: Diagnostic Repligen recommended stockholders vote for an amended stockholder proposal submitted by Ronald Chez to increase the proposed threshold necessary for …

    Published on 5/14/2012
  • Takeda gastrointestinal news

    Takeda Pharmaceutical Co. Ltd. (Tokyo:4502), Osaka, Japan Business: Gastrointestinal Takeda submitted a new request for reconsideration to the Osaka Regional Tax Bureau (ORTB) in which the company requested the bureau …

    Published on 5/14/2012
  • Aerocrine diagnostic news

    Aerocrine AB (SSE:AERO) Solna, Sweden Business: Diagnostic The U.S. Bankruptcy Court for the Northern District of California awarded Aerocrine $1.3 million to resolve patent infringement claims against now-defunct …

    Published on 5/7/2012
  • BGI, George Mason University, Massachusetts Eye and Ear Infirmary, University of Oklahoma genomics news

    BGI, Shenzhen, China George Mason University, Fairfax, Va. Massachusetts Eye and Ear Infirmary, Boston, Mass. University of Oklahoma, Norman, Okla. Business: Genomics BGI partnered with George Mason University, the …

    Published on 5/7/2012

< Previous   1  2  3  4  5  Next >
Subscribe Now
Free Trial

About BioCentury

Decision-shaping business intelligence for the global biotech and pharma industry since 1993

Log In


Forgot password  |  Forgot Login


If you are a subscriber, but have forgotten or have never received a password, please go here and ask us to send you a new one.

Catalent

Week in Review

The biotech industry's most complete compendium of corporate, clinical and financial transactions provides an efficient surveillance system for:

  • Deals
  • Regulatory Events
  • Clinical Results
  • Financings
  • Management News

Need custom ComputerVision Software?